Arcus Biosciences, Inc. — Director's Dealing 2023

Mar 10, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2023-03-09

Reporting Person: Azoy Alexander (Chief Accounting Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	690	Direct
Common Stock	216	Direct
Common Stock	3187	Direct
Common Stock	2375	Direct
Common Stock	5128	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$21.53	2030-11-07	Common Stock (87500)		Direct
Stock Option (Right to Buy)	$31.49	2031-03-07	Common Stock (867)		Direct
Stock Option (Right to Buy)	$33.03	2032-03-08	Common Stock (8500)		Direct
Stock Option (Right to Buy)	$22.02	2033-01-22	Common Stock (9500)		Direct

Footnotes

F1: Represents restricted stock units that were granted on March 8, 2021. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

F2: Represents restricted stock units that were granted on March 8, 2022. The remaining RSUs will vest in three equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

F3: Represents restricted stock units that were granted on December 15, 2022. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

F4: Represents restricted stock units that were granted on January 23, 2023. The remaining RSUs will vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

F5: This option was granted on November 9, 2020, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 45,833 of the shares of common stock subject to this option were exercisable.

F6: This option was granted on March 8, 2021, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 470 of the shares of common stock subject to this option were exercisable.

F7: This option was granted on March 8, 2022 with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 2,479 of the shares of common stock subject to this option were exercisable.

F8: This option was granted on January 23, 2023, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 396 of the shares of common stock subject to this option were exercisable.